Revolution’s aftermath: population based cross-sectional study to understand the intergeneration mental health and wellbeing following the 2024 student-led uprising
Comparative efficacy of non-pharmacological therapies in adolescents with subthreshold depression: a systematic review and network meta-analysis
RESCUE- expected usefulness and willingness to participate in a trauma-informed group intervention for coping with traumatic work experiences in the emergency medical services
Editorial: Case reports in psychopharmacology, volume IV
Harnessing the power of biomarkers for diffuse intrinsic pontine gliomas
Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04399-2
The BIOMEDE trial, although negative for its primary endpoint, illustrates the utility of adaptive trial designs and biopsy-informed tumor profiling in guiding treatment decisions and patient counseling — and provides mechanistic evidence that can inform future therapeutic strategies.
Brazil’s big bet on mosquitos
Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04388-5
As Brazil takes its modified mosquito program from pilot to practice at national scale, what will it take to beat dengue?
Genomic epidemiology of the 2025 mpox epidemic in Sierra Leone
Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04385-8
A phylogenetic analysis examined the origins of the first mpox outbreak in Sierra Leone and found evidence of an emerging lineage (G.1) that has likely descended from the Nigerian epidemic and emerged in Sierra Leone months before first detection.
Data-Driven Decision Support in Obesity Management Commission: enabling more equitable and personalized obesity care
Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04363-0
Announced in this Comment and in collaboration with Nature Medicine is the convening of the Data-Driven Decision Support in Obesity Management Commission, to promote adequate scientific evidence to support obesity management across global populations.
CRISPR−Cas9 CD33-deleted allogeneic hematopoietic cell transplantation with gemtuzumab ozogamicin maintenance in AML: a phase 1/2 trial
Nature Medicine, Published online: 12 May 2026; doi:10.1038/s41591-026-04362-1
In a first-in-human trial combining the transplantation of CD33-negative CRISPR-edited hematopoietic cells with the CD33-targeted antibody–drug conjugate gemtuzumab ozogamicin, all transplanted patients achieved primary engraftment, and the treatment was well tolerated.

